Cinclus Pharma Holding AB (publ) CINPHA
Updated: 8 Aug 2026
No signal published yet
We already track Cinclus Pharma Holding and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Cinclus Pharma Holding AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Cinclus Pharma Holding free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 2, 2026, Cinclus Pharma announced that it reached its patient enrollment target in the pivotal Phase III HEEALING1 study for linaprazan glurate. The study evaluates the candidate for the treatment of erosive gastroesophageal reflux disease, with topline results expected in the fourth quarter of 2026.
What Firelda Watch includes for Cinclus Pharma Holding AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Cinclus Pharma Holding AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Cinclus Pharma Holding free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more